As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/13/20  Acadia Pharmaceuticals Inc        8-K:2,9     1/13/20   11:8.5M                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     36K 
10: R1          Document and Entity Information                     HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 8: XML         XBRL Instance -- d869733d8k_htm                      XML     13K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- acad-20200113_lab                     XML     55K 
 5: EX-101.PRE  XBRL Presentations -- acad-20200113_pre              XML     35K 
 3: EX-101.SCH  XBRL Schema -- acad-20200113                         XSD     12K 
 7: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
 6: ZIP         XBRL Zipped Folder -- 0001193125-20-005813-xbrl      Zip     16K 

 i ACADIA PHARMACEUTICALS INC  i false  i 0001070494 0001070494 2020-01-13 2020-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM  i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i January 13, 2020

ACADIA Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

i Delaware		i 000-50768		i 06-1376651
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification No.)

i 3611 Valley Centre Drive,  i Suite 300  i San Diego,  i California				i 92130
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code:  i (858)  i 558-2871

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

i ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, par value $0.0001 per share		i ACAD		i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company   i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02

Results of Operations and Financial Condition.

On January 13, 2020, in advance of meetings and its presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, ACADIA Pharmaceuticals Inc. is making publicly available a corporate presentation that includes information and updates regarding its business. A copy of the presentation is attached as Exhibit 99.1 hereto.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.				Description
	99.1			Presentation of ACADIA Pharmaceuticals Inc., made available on January 13, 2020.
	104			Cover page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2020				ACADIA Pharmaceuticals Inc.
				By:		/s/ Austin D. Kim
				Name:		Austin D. Kim
				Title:		Executive Vice President, General Counsel & Secretary